Frequently Asked Questions
What does Castle Biosciences do?
Castle Biosciences is a molecular diagnostics company that provid Read More
About MEG
This author has not yet filled in any details.So far MEG has created 67 blog entries.
Cernostics CEO on the opportunities ahead with Castle’s acquisition
Cernostics CEO Michael Hoerres said his biotech company’s presence will not just remain but grow in Pittsburgh with the Read More
Cernostics Contracts with Geisinger Health Plan to Become an In-network Provider for TissueCypher® Barrett’s Esophagus Assay
Cernostics, pioneer of the worlds’ first precision medicine test to predict future development risk of esophageal cancer from Barrett’s esophagus (BE), TissueCypher® Barrett’s Esophagus Assay, has become a participating (“in-network”) provider for Geisinger Health Plan (GHP)’s more than 550,000 plan members in Central, North Central and East Central Pennsylvania. Read More
Digestive Disease Week® 2021 to Showcase the TissueCypher® Barrett’s Esophagus Assay as a Paradigm-shifting Precision Medicine Tool
Mayo Clinic and AMC Amsterdam to Present Data on Predicting Progression to Esophageal C Read More
Cernostics Announces Blinded, Independent Validation of TissueCypher ® Performance for Predicting Risk of Progression to Esophageal Cancer in Patients with Non-Dysplastic BE
Study further validates TissueCypher® as the first and only precision medicine test proven to provide actionable dat Read More
Cernostics Announces Groundbreaking Data Demonstrating TissueCypher® Performance for Predicting Risk of Progression to EAC in Patients with Non-Dysplastic BE
First-of-its-kind precision medicine test for esophageal pinch biopsies identifies high risk non-dysplasti Read More
TissueCypher® Further Validated to Accurately Risk Stratify Barrett’s Esophagus Patients with Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences
Data presented at ACG, UEGW illustrates the 4th independent validation of TissueCypher performance for risk stratify Read More
Cernostics Announces Formation of Distinguished Medical Advisory Board Including Top Specialists in All Facets of Esophageal Disease
PITTSBURGH, Penn., July 1, 2019 — Cernostics, developer of next-generation cancer diagnostics Read More
Research Validates Tissue Pathology Test Predicting Progression in Barrett’s Esophagus
Objective risk assessment guides surveillance and treatment
Patients with Barrett’s es Read More